Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al

Ann Oncol. 2016 Apr;27(4):750-1. doi: 10.1093/annonc/mdw023. Epub 2016 Jan 22.

Authors

C Parker¹, S Gillessen², A Heidenreich³, A Horwich⁴

Affiliations

¹ Clinical Oncology Academic Unit, Royal Marsden NHS Foundation Trust, Sutton, UK chris.parker@icr.ac.uk.
² Department of Oncology and Hematology, Kantonsspital, St Gallen, Switzerland.
³ Department of Urology, RWTH University Aachen, Germany.
⁴ Department of Clinical Oncology, Academic Unit, Royal Marsden NHS Trust, Sutton, UK.

PMID: 26802159
DOI: 10.1093/annonc/mdw023

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Male
Prostate / pathology*
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / therapy*